id	sid	tid	token	lemma	pos
cord-309914-1lpl26eo	1	1	key	key	JJ
cord-309914-1lpl26eo	1	2	:	:	:
cord-309914-1lpl26eo	1	3	cord-309914	cord-309914	NNP
cord-309914-1lpl26eo	1	4	-	-	HYPH
cord-309914-1lpl26eo	1	5	1lpl26eo	1lpl26eo	CD
cord-309914-1lpl26eo	1	6	authors	author	NNS
cord-309914-1lpl26eo	1	7	:	:	:
cord-309914-1lpl26eo	1	8	Peterson	Peterson	NNP
cord-309914-1lpl26eo	1	9	,	,	,
cord-309914-1lpl26eo	1	10	Danielle	Danielle	NNP
cord-309914-1lpl26eo	1	11	;	;	:
cord-309914-1lpl26eo	1	12	Damsky	Damsky	NNP
cord-309914-1lpl26eo	1	13	,	,	,
cord-309914-1lpl26eo	1	14	William	William	NNP
cord-309914-1lpl26eo	1	15	;	;	:
cord-309914-1lpl26eo	1	16	King	King	NNP
cord-309914-1lpl26eo	1	17	,	,	,
cord-309914-1lpl26eo	1	18	Brett	Brett	NNP
cord-309914-1lpl26eo	1	19	title	title	NN
cord-309914-1lpl26eo	1	20	:	:	:
cord-309914-1lpl26eo	1	21	The	the	DT
cord-309914-1lpl26eo	1	22	use	use	NN
cord-309914-1lpl26eo	1	23	of	of	IN
cord-309914-1lpl26eo	1	24	Janus	Janus	NNP
cord-309914-1lpl26eo	1	25	kinase	kinase	NN
cord-309914-1lpl26eo	1	26	inhibitors	inhibitor	NNS
cord-309914-1lpl26eo	1	27	in	in	IN
cord-309914-1lpl26eo	1	28	the	the	DT
cord-309914-1lpl26eo	1	29	time	time	NN
cord-309914-1lpl26eo	1	30	of	of	IN
cord-309914-1lpl26eo	1	31	SARS	SARS	NNP
cord-309914-1lpl26eo	1	32	-	-	HYPH
cord-309914-1lpl26eo	1	33	CoV-2	CoV-2	NNP
cord-309914-1lpl26eo	1	34	date	date	NN
cord-309914-1lpl26eo	1	35	:	:	:
cord-309914-1lpl26eo	1	36	2020	2020	CD
cord-309914-1lpl26eo	1	37	-	-	HYPH
cord-309914-1lpl26eo	1	38	04	04	CD
cord-309914-1lpl26eo	1	39	-	-	HYPH
cord-309914-1lpl26eo	1	40	09	09	CD
cord-309914-1lpl26eo	1	41	journal	journal	NN
cord-309914-1lpl26eo	1	42	:	:	:
cord-309914-1lpl26eo	2	1	J	J	NNP
cord-309914-1lpl26eo	2	2	Am	be	VBP
cord-309914-1lpl26eo	3	1	Acad	Acad	NNP
cord-309914-1lpl26eo	3	2	Dermatol	Dermatol	NNP
cord-309914-1lpl26eo	4	1	DOI	DOI	NNP
cord-309914-1lpl26eo	4	2	:	:	:
cord-309914-1lpl26eo	5	1	10.1016	10.1016	CD
cord-309914-1lpl26eo	5	2	/	/	SYM
cord-309914-1lpl26eo	5	3	j.jaad.2020.03.099	j.jaad.2020.03.099	CD
cord-309914-1lpl26eo	5	4	sha	sha	NN
cord-309914-1lpl26eo	5	5	:	:	:
cord-309914-1lpl26eo	5	6	ad5dd2193095b5ede55e2968d10c5c2541a5ccf7	ad5dd2193095b5ede55e2968d10c5c2541a5ccf7	NNP
cord-309914-1lpl26eo	5	7	doc_id	doc_id	NNPS
cord-309914-1lpl26eo	5	8	:	:	:
cord-309914-1lpl26eo	5	9	309914	309914	CD
cord-309914-1lpl26eo	5	10	cord_uid	cord_uid	FW
cord-309914-1lpl26eo	5	11	:	:	:
cord-309914-1lpl26eo	6	1	1lpl26eo	1lpl26eo	CD
cord-309914-1lpl26eo	6	2	nan	nan	NNP
cord-309914-1lpl26eo	7	1	During	during	IN
cord-309914-1lpl26eo	7	2	the	the	DT
cord-309914-1lpl26eo	7	3	time	time	NN
cord-309914-1lpl26eo	7	4	of	of	IN
cord-309914-1lpl26eo	7	5	the	the	DT
cord-309914-1lpl26eo	7	6	SARS	SARS	NNP
cord-309914-1lpl26eo	7	7	-	-	HYPH
cord-309914-1lpl26eo	7	8	CoV-2	CoV-2	NNP
cord-309914-1lpl26eo	7	9	pandemic	pandemic	NN
cord-309914-1lpl26eo	7	10	,	,	,
cord-309914-1lpl26eo	7	11	questions	question	NNS
cord-309914-1lpl26eo	7	12	arise	arise	VBP
cord-309914-1lpl26eo	7	13	regarding	regard	VBG
cord-309914-1lpl26eo	7	14	patients	patient	NNS
cord-309914-1lpl26eo	7	15	being	be	VBG
cord-309914-1lpl26eo	7	16	treated	treat	VBN
cord-309914-1lpl26eo	7	17	with	with	IN
cord-309914-1lpl26eo	7	18	37	37	CD
cord-309914-1lpl26eo	7	19	immunomodulatory	immunomodulatory	JJ
cord-309914-1lpl26eo	7	20	therapies	therapy	NNS
cord-309914-1lpl26eo	7	21	.	.	.
cord-309914-1lpl26eo	8	1	In	in	IN
cord-309914-1lpl26eo	8	2	particular	particular	JJ
cord-309914-1lpl26eo	8	3	,	,	,
cord-309914-1lpl26eo	8	4	is	be	VBZ
cord-309914-1lpl26eo	8	5	there	there	EX
cord-309914-1lpl26eo	8	6	an	an	DT
cord-309914-1lpl26eo	8	7	increased	increase	VBN
cord-309914-1lpl26eo	8	8	risk	risk	NN
cord-309914-1lpl26eo	8	9	of	of	IN
cord-309914-1lpl26eo	8	10	acquiring	acquire	VBG
cord-309914-1lpl26eo	8	11	the	the	DT
cord-309914-1lpl26eo	8	12	infection	infection	NN
cord-309914-1lpl26eo	8	13	or	or	CC
cord-309914-1lpl26eo	8	14	38	38	CD
cord-309914-1lpl26eo	8	15	experiencing	experience	VBG
cord-309914-1lpl26eo	8	16	a	a	DT
cord-309914-1lpl26eo	8	17	worse	bad	JJR
cord-309914-1lpl26eo	8	18	outcome	outcome	NN
cord-309914-1lpl26eo	8	19	from	from	IN
cord-309914-1lpl26eo	8	20	SARS	SARS	NNP
cord-309914-1lpl26eo	8	21	-	-	HYPH
cord-309914-1lpl26eo	8	22	CoV-2	CoV-2	NNP
cord-309914-1lpl26eo	8	23	?	?	.
cord-309914-1lpl26eo	9	1	While	while	IN
cord-309914-1lpl26eo	9	2	this	this	DT
cord-309914-1lpl26eo	9	3	exact	exact	JJ
cord-309914-1lpl26eo	9	4	question	question	NN
cord-309914-1lpl26eo	9	5	is	be	VBZ
cord-309914-1lpl26eo	9	6	presently	presently	RB
cord-309914-1lpl26eo	9	7	unanswerable	unanswerable	JJ
cord-309914-1lpl26eo	9	8	,	,	,
cord-309914-1lpl26eo	9	9	39	39	CD
cord-309914-1lpl26eo	9	10	we	-PRON-	PRP
cord-309914-1lpl26eo	9	11	can	can	MD
cord-309914-1lpl26eo	9	12	look	look	VB
cord-309914-1lpl26eo	9	13	at	at	IN
cord-309914-1lpl26eo	9	14	safety	safety	NN
cord-309914-1lpl26eo	9	15	data	datum	NNS
cord-309914-1lpl26eo	9	16	from	from	IN
cord-309914-1lpl26eo	9	17	clinical	clinical	JJ
cord-309914-1lpl26eo	9	18	trials	trial	NNS
cord-309914-1lpl26eo	9	19	to	to	TO
cord-309914-1lpl26eo	9	20	try	try	VB
cord-309914-1lpl26eo	9	21	to	to	TO
cord-309914-1lpl26eo	9	22	understand	understand	VB
cord-309914-1lpl26eo	9	23	patient	patient	JJ
cord-309914-1lpl26eo	9	24	susceptibility	susceptibility	NN
cord-309914-1lpl26eo	9	25	to	to	IN
cord-309914-1lpl26eo	9	26	different	different	JJ
cord-309914-1lpl26eo	9	27	40	40	CD
cord-309914-1lpl26eo	9	28	infections	infection	NNS
cord-309914-1lpl26eo	9	29	.	.	.
cord-309914-1lpl26eo	10	1	While	while	IN
cord-309914-1lpl26eo	10	2	others	other	NNS
cord-309914-1lpl26eo	10	3	have	have	VBP
cord-309914-1lpl26eo	10	4	addressed	address	VBN
cord-309914-1lpl26eo	10	5	this	this	DT
cord-309914-1lpl26eo	10	6	in	in	IN
cord-309914-1lpl26eo	10	7	the	the	DT
cord-309914-1lpl26eo	10	8	context	context	NN
cord-309914-1lpl26eo	10	9	of	of	IN
cord-309914-1lpl26eo	10	10	biologic	biologic	JJ
cord-309914-1lpl26eo	10	11	1	1	CD
cord-309914-1lpl26eo	10	12	or	or	CC
cord-309914-1lpl26eo	10	13	classical	classical	JJ
cord-309914-1lpl26eo	10	14	small	small	JJ
cord-309914-1lpl26eo	10	15	molecule	molecule	NN
cord-309914-1lpl26eo	10	16	41	41	CD
cord-309914-1lpl26eo	10	17	therapy	therapy	NN
cord-309914-1lpl26eo	10	18	2	2	CD
cord-309914-1lpl26eo	10	19	,	,	,
cord-309914-1lpl26eo	10	20	the	the	DT
cord-309914-1lpl26eo	10	21	risk	risk	NN
cord-309914-1lpl26eo	10	22	of	of	IN
cord-309914-1lpl26eo	10	23	Janus	Janus	NNP
cord-309914-1lpl26eo	10	24	kinase	kinase	NN
cord-309914-1lpl26eo	10	25	inhibitor	inhibitor	NN
cord-309914-1lpl26eo	10	26	(	(	-LRB-
cord-309914-1lpl26eo	10	27	JAKi	JAKi	NNS
cord-309914-1lpl26eo	10	28	)	)	-RRB-
cord-309914-1lpl26eo	10	29	treatment	treatment	NN
cord-309914-1lpl26eo	10	30	has	have	VBZ
cord-309914-1lpl26eo	10	31	not	not	RB
cord-309914-1lpl26eo	10	32	been	be	VBN
cord-309914-1lpl26eo	10	33	addressed	address	VBN
cord-309914-1lpl26eo	10	34	.	.	.
cord-309914-1lpl26eo	11	1	In	in	IN
cord-309914-1lpl26eo	11	2	light	light	NN
cord-309914-1lpl26eo	11	3	of	of	IN
cord-309914-1lpl26eo	11	4	the	the	DT
cord-309914-1lpl26eo	11	5	42	42	CD
cord-309914-1lpl26eo	11	6	growing	grow	VBG
cord-309914-1lpl26eo	11	7	off	off	IN
cord-309914-1lpl26eo	11	8	-	-	HYPH
cord-309914-1lpl26eo	11	9	label	label	NN
cord-309914-1lpl26eo	11	10	use	use	NN
cord-309914-1lpl26eo	11	11	of	of	IN
cord-309914-1lpl26eo	11	12	JAKi	JAKi	NNS
cord-309914-1lpl26eo	11	13	in	in	IN
cord-309914-1lpl26eo	11	14	dermatology	dermatology	NN
cord-309914-1lpl26eo	11	15	in	in	IN
cord-309914-1lpl26eo	11	16	addition	addition	NN
cord-309914-1lpl26eo	11	17	to	to	IN
cord-309914-1lpl26eo	11	18	pharmaceutical	pharmaceutical	NN
cord-309914-1lpl26eo	11	19	industry	industry	NN
cord-309914-1lpl26eo	11	20	sponsored	sponsor	VBD
cord-309914-1lpl26eo	11	21	clinical	clinical	JJ
cord-309914-1lpl26eo	11	22	43	43	CD
cord-309914-1lpl26eo	11	23	trials	trial	NNS
cord-309914-1lpl26eo	11	24	of	of	IN
cord-309914-1lpl26eo	11	25	JAKi	JAKi	NNS
cord-309914-1lpl26eo	11	26	for	for	IN
cord-309914-1lpl26eo	11	27	alopecia	alopecia	NNP
cord-309914-1lpl26eo	11	28	areata	areata	NNP
cord-309914-1lpl26eo	11	29	,	,	,
cord-309914-1lpl26eo	11	30	atopic	atopic	JJ
cord-309914-1lpl26eo	11	31	dermatitis	dermatitis	NN
cord-309914-1lpl26eo	11	32	,	,	,
cord-309914-1lpl26eo	11	33	vitiligo	vitiligo	NN
cord-309914-1lpl26eo	11	34	,	,	,
cord-309914-1lpl26eo	11	35	etc	etc	FW
cord-309914-1lpl26eo	11	36	,	,	,
cord-309914-1lpl26eo	11	37	dermatologists	dermatologist	NNS
cord-309914-1lpl26eo	11	38	need	need	VBP
cord-309914-1lpl26eo	11	39	data	datum	NNS
cord-309914-1lpl26eo	11	40	to	to	IN
cord-309914-1lpl26eo	11	41	better	well	JJR
cord-309914-1lpl26eo	11	42	44	44	CD
cord-309914-1lpl26eo	11	43	understand	understand	VB
cord-309914-1lpl26eo	11	44	the	the	DT
cord-309914-1lpl26eo	11	45	risks	risk	NNS
cord-309914-1lpl26eo	11	46	of	of	IN
cord-309914-1lpl26eo	11	47	JAKi	JAKi	NNS
cord-309914-1lpl26eo	11	48	treatment	treatment	NN
cord-309914-1lpl26eo	11	49	in	in	IN
cord-309914-1lpl26eo	11	50	order	order	NN
cord-309914-1lpl26eo	11	51	to	to	TO
cord-309914-1lpl26eo	11	52	best	good	JJS
cord-309914-1lpl26eo	11	53	manage	manage	VB
cord-309914-1lpl26eo	11	54	and	and	CC
cord-309914-1lpl26eo	11	55	counsel	counsel	VB
cord-309914-1lpl26eo	11	56	our	-PRON-	PRP$
cord-309914-1lpl26eo	11	57	patients	patient	NNS
cord-309914-1lpl26eo	11	58	during	during	IN
cord-309914-1lpl26eo	11	59	this	this	DT
cord-309914-1lpl26eo	11	60	45	45	CD
cord-309914-1lpl26eo	11	61	unique	unique	JJ
cord-309914-1lpl26eo	11	62	time	time	NN
cord-309914-1lpl26eo	11	63	.	.	.
cord-309914-1lpl26eo	12	1	46	46	CD
cord-309914-1lpl26eo	13	1	We	-PRON-	PRP
cord-309914-1lpl26eo	13	2	analyzed	analyze	VBD
cord-309914-1lpl26eo	13	3	and	and	CC
cord-309914-1lpl26eo	13	4	collated	collate	VBD
cord-309914-1lpl26eo	13	5	Adverse	adverse	JJ
cord-309914-1lpl26eo	13	6	Events	Events	NNPS
cord-309914-1lpl26eo	13	7	data	datum	NNS
cord-309914-1lpl26eo	13	8	from	from	IN
cord-309914-1lpl26eo	13	9	JAKi	JAKi	NNP
cord-309914-1lpl26eo	13	10	clinical	clinical	JJ
cord-309914-1lpl26eo	13	11	trials	trial	NNS
cord-309914-1lpl26eo	13	12	.	.	.
cord-309914-1lpl26eo	14	1	In	in	IN
cord-309914-1lpl26eo	14	2	particular	particular	JJ
cord-309914-1lpl26eo	14	3	,	,	,
cord-309914-1lpl26eo	14	4	we	-PRON-	PRP
cord-309914-1lpl26eo	14	5	focused	focus	VBD
cord-309914-1lpl26eo	14	6	on	on	IN
cord-309914-1lpl26eo	14	7	48	48	CD
cord-309914-1lpl26eo	14	8	infections	infection	NNS
cord-309914-1lpl26eo	14	9	and	and	CC
cord-309914-1lpl26eo	14	10	pulmonary	pulmonary	JJ
cord-309914-1lpl26eo	14	11	toxicities	toxicity	NNS
cord-309914-1lpl26eo	14	12	observed	observe	VBN
cord-309914-1lpl26eo	14	13	across	across	IN
cord-309914-1lpl26eo	14	14	the	the	DT
cord-309914-1lpl26eo	14	15	different	different	JJ
cord-309914-1lpl26eo	14	16	FDA	FDA	NNP
cord-309914-1lpl26eo	14	17	-	-	HYPH
cord-309914-1lpl26eo	14	18	approved	approve	VBN
cord-309914-1lpl26eo	14	19	JAKi	JAKi	NNS
cord-309914-1lpl26eo	14	20	for	for	IN
cord-309914-1lpl26eo	14	21	their	-PRON-	PRP$
cord-309914-1lpl26eo	14	22	FDA-49	FDA-49	NNP
cord-309914-1lpl26eo	14	23	approved	approve	VBN
cord-309914-1lpl26eo	14	24	indications	indication	NNS
cord-309914-1lpl26eo	14	25	.	.	.
cord-309914-1lpl26eo	15	1	When	when	WRB
cord-309914-1lpl26eo	15	2	available	available	JJ
cord-309914-1lpl26eo	15	3	,	,	,
cord-309914-1lpl26eo	15	4	data	datum	NNS
cord-309914-1lpl26eo	15	5	from	from	IN
cord-309914-1lpl26eo	15	6	phase	phase	NN
cord-309914-1lpl26eo	15	7	II	II	NNP
cord-309914-1lpl26eo	15	8	or	or	CC
cord-309914-1lpl26eo	15	9	III	iii	CD
cord-309914-1lpl26eo	15	10	clinical	clinical	JJ
cord-309914-1lpl26eo	15	11	trials	trial	NNS
cord-309914-1lpl26eo	15	12	for	for	IN
cord-309914-1lpl26eo	15	13	dermatological	dermatological	JJ
cord-309914-1lpl26eo	15	14	50	50	CD
cord-309914-1lpl26eo	15	15	indications	indication	NNS
cord-309914-1lpl26eo	15	16	was	be	VBD
cord-309914-1lpl26eo	15	17	included	include	VBN
cord-309914-1lpl26eo	15	18	.	.	.
cord-309914-1lpl26eo	16	1	Table	table	NN
cord-309914-1lpl26eo	16	2	1	1	CD
cord-309914-1lpl26eo	16	3	shows	show	VBZ
cord-309914-1lpl26eo	16	4	the	the	DT
cord-309914-1lpl26eo	16	5	rates	rate	NNS
cord-309914-1lpl26eo	16	6	of	of	IN
cord-309914-1lpl26eo	16	7	various	various	JJ
cord-309914-1lpl26eo	16	8	infections	infection	NNS
cord-309914-1lpl26eo	16	9	,	,	,
cord-309914-1lpl26eo	16	10	including	include	VBG
cord-309914-1lpl26eo	16	11	upper	upper	JJ
cord-309914-1lpl26eo	16	12	respiratory	respiratory	JJ
cord-309914-1lpl26eo	16	13	51	51	CD
cord-309914-1lpl26eo	16	14	infections	infection	NNS
cord-309914-1lpl26eo	16	15	,	,	,
cord-309914-1lpl26eo	16	16	nasopharyngitis	nasopharyngitis	NN
cord-309914-1lpl26eo	16	17	and	and	CC
cord-309914-1lpl26eo	16	18	influenza	influenza	NN
cord-309914-1lpl26eo	16	19	,	,	,
cord-309914-1lpl26eo	16	20	for	for	IN
cord-309914-1lpl26eo	16	21	JAKi	JAKi	NNS
cord-309914-1lpl26eo	16	22	-	-	HYPH
cord-309914-1lpl26eo	16	23	treated	treat	VBN
cord-309914-1lpl26eo	16	24	groups	group	NNS
cord-309914-1lpl26eo	16	25	versus	versus	IN
cord-309914-1lpl26eo	16	26	placebo	placebo	NN
cord-309914-1lpl26eo	16	27	groups	group	NNS
cord-309914-1lpl26eo	16	28	.	.	.
cord-309914-1lpl26eo	17	1	Overall	overall	RB
cord-309914-1lpl26eo	17	2	,	,	,
cord-309914-1lpl26eo	17	3	rates	rate	NNS
cord-309914-1lpl26eo	17	4	52	52	CD
cord-309914-1lpl26eo	17	5	of	of	IN
cord-309914-1lpl26eo	17	6	infectious	infectious	JJ
cord-309914-1lpl26eo	17	7	events	event	NNS
cord-309914-1lpl26eo	17	8	are	be	VBP
cord-309914-1lpl26eo	17	9	only	only	RB
cord-309914-1lpl26eo	17	10	mildly	mildly	RB
cord-309914-1lpl26eo	17	11	increased	increase	VBN
cord-309914-1lpl26eo	17	12	in	in	IN
cord-309914-1lpl26eo	17	13	JAKi	JAKi	NNS
cord-309914-1lpl26eo	17	14	-	-	HYPH
cord-309914-1lpl26eo	17	15	treated	treat	VBN
cord-309914-1lpl26eo	17	16	patients	patient	NNS
cord-309914-1lpl26eo	17	17	.	.	.
cord-309914-1lpl26eo	18	1	We	-PRON-	PRP
cord-309914-1lpl26eo	18	2	also	also	RB
cord-309914-1lpl26eo	18	3	collated	collate	VBD
cord-309914-1lpl26eo	18	4	pulmonary	pulmonary	JJ
cord-309914-1lpl26eo	18	5	53	53	CD
cord-309914-1lpl26eo	18	6	toxicities	toxicity	NNS
cord-309914-1lpl26eo	18	7	of	of	IN
cord-309914-1lpl26eo	18	8	JAKi	JAKi	NNS
cord-309914-1lpl26eo	18	9	to	to	TO
cord-309914-1lpl26eo	18	10	identify	identify	VB
cord-309914-1lpl26eo	18	11	potential	potential	JJ
cord-309914-1lpl26eo	18	12	risks	risk	NNS
cord-309914-1lpl26eo	18	13	of	of	IN
cord-309914-1lpl26eo	18	14	worsening	worsen	VBG
cord-309914-1lpl26eo	18	15	severe	severe	JJ
cord-309914-1lpl26eo	18	16	respiratory	respiratory	JJ
cord-309914-1lpl26eo	18	17	disease	disease	NN
cord-309914-1lpl26eo	18	18	from	from	IN
cord-309914-1lpl26eo	18	19	SARS	SARS	NNP
cord-309914-1lpl26eo	18	20	-	-	HYPH
cord-309914-1lpl26eo	18	21	CoV-2	CoV-2	NNP
cord-309914-1lpl26eo	18	22	,	,	,
cord-309914-1lpl26eo	18	23	and	and	CC
cord-309914-1lpl26eo	18	24	54	54	CD
cord-309914-1lpl26eo	18	25	such	such	JJ
cord-309914-1lpl26eo	18	26	toxicities	toxicity	NNS
cord-309914-1lpl26eo	18	27	are	be	VBP
cord-309914-1lpl26eo	18	28	all	all	RB
cord-309914-1lpl26eo	18	29	but	but	CC
cord-309914-1lpl26eo	18	30	absent	absent	JJ
cord-309914-1lpl26eo	18	31	.	.	.
cord-309914-1lpl26eo	19	1	55	55	CD
cord-309914-1lpl26eo	19	2	56	56	CD
cord-309914-1lpl26eo	20	1	In	in	IN
cord-309914-1lpl26eo	20	2	order	order	NN
cord-309914-1lpl26eo	20	3	to	to	TO
cord-309914-1lpl26eo	20	4	understand	understand	VB
cord-309914-1lpl26eo	20	5	the	the	DT
cord-309914-1lpl26eo	20	6	infection	infection	NN
cord-309914-1lpl26eo	20	7	data	datum	NNS
cord-309914-1lpl26eo	20	8	,	,	,
cord-309914-1lpl26eo	20	9	it	-PRON-	PRP
cord-309914-1lpl26eo	20	10	is	be	VBZ
cord-309914-1lpl26eo	20	11	helpful	helpful	JJ
cord-309914-1lpl26eo	20	12	to	to	TO
cord-309914-1lpl26eo	20	13	understand	understand	VB
cord-309914-1lpl26eo	20	14	the	the	DT
cord-309914-1lpl26eo	20	15	mechanism	mechanism	NN
cord-309914-1lpl26eo	20	16	and	and	CC
cord-309914-1lpl26eo	20	17	57	57	CD
cord-309914-1lpl26eo	20	18	pharmacokinetics	pharmacokinetic	NNS
cord-309914-1lpl26eo	20	19	of	of	IN
cord-309914-1lpl26eo	20	20	JAKi	JAKi	NNS
cord-309914-1lpl26eo	20	21	.	.	.
cord-309914-1lpl26eo	21	1	Cytokines	cytokine	NNS
cord-309914-1lpl26eo	21	2	can	can	MD
cord-309914-1lpl26eo	21	3	drive	drive	VB
cord-309914-1lpl26eo	21	4	autoimmunity	autoimmunity	NN
cord-309914-1lpl26eo	21	5	when	when	WRB
cord-309914-1lpl26eo	21	6	their	-PRON-	PRP$
cord-309914-1lpl26eo	21	7	activity	activity	NN
cord-309914-1lpl26eo	21	8	is	be	VBZ
cord-309914-1lpl26eo	21	9	exaggerated	exaggerate	VBN
cord-309914-1lpl26eo	21	10	(	(	-LRB-
cord-309914-1lpl26eo	21	11	Figure	figure	NN
cord-309914-1lpl26eo	21	12	3	3	CD
cord-309914-1lpl26eo	21	13	1A	1a	CD
cord-309914-1lpl26eo	21	14	)	)	-RRB-
cord-309914-1lpl26eo	21	15	.	.	.
cord-309914-1lpl26eo	22	1	JAKi	JAKi	NNP
cord-309914-1lpl26eo	22	2	,	,	,
cord-309914-1lpl26eo	22	3	which	which	WDT
cord-309914-1lpl26eo	22	4	are	be	VBP
cord-309914-1lpl26eo	22	5	taken	take	VBN
cord-309914-1lpl26eo	22	6	orally	orally	RB
cord-309914-1lpl26eo	22	7	1	1	CD
cord-309914-1lpl26eo	22	8	-	-	SYM
cord-309914-1lpl26eo	22	9	2	2	CD
cord-309914-1lpl26eo	22	10	times	time	NNS
cord-309914-1lpl26eo	22	11	per	per	IN
cord-309914-1lpl26eo	22	12	day	day	NN
cord-309914-1lpl26eo	22	13	,	,	,
cord-309914-1lpl26eo	22	14	largely	largely	RB
cord-309914-1lpl26eo	22	15	impact	impact	NN
cord-309914-1lpl26eo	22	16	pathogenically	pathogenically	RB
cord-309914-1lpl26eo	22	17	elevated	elevated	JJ
cord-309914-1lpl26eo	22	18	cytokine	cytokine	NN
cord-309914-1lpl26eo	22	19	59	59	CD
cord-309914-1lpl26eo	22	20	activity	activity	NN
cord-309914-1lpl26eo	22	21	,	,	,
cord-309914-1lpl26eo	22	22	with	with	IN
cord-309914-1lpl26eo	22	23	relative	relative	JJ
cord-309914-1lpl26eo	22	24	sparing	sparing	NN
cord-309914-1lpl26eo	22	25	of	of	IN
cord-309914-1lpl26eo	22	26	normal	normal	JJ
cord-309914-1lpl26eo	22	27	cytokine	cytokine	NN
cord-309914-1lpl26eo	22	28	activity	activity	NN
cord-309914-1lpl26eo	22	29	because	because	IN
cord-309914-1lpl26eo	22	30	drug	drug	NN
cord-309914-1lpl26eo	22	31	concentrations	concentration	NNS
cord-309914-1lpl26eo	22	32	are	be	VBP
cord-309914-1lpl26eo	22	33	sub-60	sub-60	NNP
cord-309914-1lpl26eo	22	34	therapeutic	therapeutic	JJ
cord-309914-1lpl26eo	22	35	for	for	IN
cord-309914-1lpl26eo	22	36	part	part	NN
cord-309914-1lpl26eo	22	37	of	of	IN
cord-309914-1lpl26eo	22	38	the	the	DT
cord-309914-1lpl26eo	22	39	day	day	NN
cord-309914-1lpl26eo	22	40	(	(	-LRB-
cord-309914-1lpl26eo	22	41	Figure	figure	NN
cord-309914-1lpl26eo	22	42	1B	1b	CD
cord-309914-1lpl26eo	23	1	In	in	IN
cord-309914-1lpl26eo	23	2	this	this	DT
cord-309914-1lpl26eo	23	3	time	time	NN
cord-309914-1lpl26eo	23	4	of	of	IN
cord-309914-1lpl26eo	23	5	the	the	DT
cord-309914-1lpl26eo	23	6	SARS	SARS	NNP
cord-309914-1lpl26eo	23	7	-	-	HYPH
cord-309914-1lpl26eo	23	8	CoV-2	CoV-2	NNP
cord-309914-1lpl26eo	23	9	pandemic	pandemic	NN
cord-309914-1lpl26eo	23	10	,	,	,
cord-309914-1lpl26eo	23	11	we	-PRON-	PRP
cord-309914-1lpl26eo	23	12	must	must	MD
cord-309914-1lpl26eo	23	13	be	be	VB
cord-309914-1lpl26eo	23	14	as	as	RB
cord-309914-1lpl26eo	23	15	informed	inform	VBN
cord-309914-1lpl26eo	23	16	as	as	IN
cord-309914-1lpl26eo	23	17	possible	possible	JJ
cord-309914-1lpl26eo	23	18	regarding	regard	VBG
cord-309914-1lpl26eo	23	19	the	the	DT
cord-309914-1lpl26eo	23	20	risks	risk	NNS
cord-309914-1lpl26eo	23	21	of	of	IN
cord-309914-1lpl26eo	23	22	the	the	DT
cord-309914-1lpl26eo	23	23	75	75	CD
cord-309914-1lpl26eo	23	24	treatments	treatment	NNS
cord-309914-1lpl26eo	23	25	we	-PRON-	PRP
cord-309914-1lpl26eo	23	26	prescribe	prescribe	VBP
cord-309914-1lpl26eo	23	27	our	-PRON-	PRP$
cord-309914-1lpl26eo	23	28	patients	patient	NNS
cord-309914-1lpl26eo	23	29	.	.	.
cord-309914-1lpl26eo	24	1	Of	of	RB
cord-309914-1lpl26eo	24	2	course	course	RB
cord-309914-1lpl26eo	24	3	,	,	,
cord-309914-1lpl26eo	24	4	shared	share	VBN
cord-309914-1lpl26eo	24	5	decision	decision	NN
cord-309914-1lpl26eo	24	6	-	-	HYPH
cord-309914-1lpl26eo	24	7	making	making	NN
cord-309914-1lpl26eo	24	8	reigns	reign	VBZ
cord-309914-1lpl26eo	24	9	supreme	supreme	JJ
cord-309914-1lpl26eo	24	10	,	,	,
cord-309914-1lpl26eo	24	11	but	but	CC
cord-309914-1lpl26eo	24	12	without	without	IN
cord-309914-1lpl26eo	24	13	76	76	CD
cord-309914-1lpl26eo	24	14	data	datum	NNS
cord-309914-1lpl26eo	24	15	we	-PRON-	PRP
cord-309914-1lpl26eo	24	16	,	,	,
cord-309914-1lpl26eo	24	17	as	as	IN
cord-309914-1lpl26eo	24	18	physicians	physician	NNS
cord-309914-1lpl26eo	24	19	,	,	,
cord-309914-1lpl26eo	24	20	will	will	MD
cord-309914-1lpl26eo	24	21	be	be	VB
cord-309914-1lpl26eo	24	22	unable	unable	JJ
cord-309914-1lpl26eo	24	23	to	to	TO
cord-309914-1lpl26eo	24	24	provide	provide	VB
cord-309914-1lpl26eo	24	25	our	-PRON-	PRP$
cord-309914-1lpl26eo	24	26	patients	patient	NNS
cord-309914-1lpl26eo	24	27	the	the	DT
cord-309914-1lpl26eo	24	28	guidance	guidance	NN
cord-309914-1lpl26eo	24	29	they	-PRON-	PRP
cord-309914-1lpl26eo	24	30	rely	rely	VBP
cord-309914-1lpl26eo	24	31	on	on	IN
cord-309914-1lpl26eo	24	32	us	-PRON-	PRP
cord-309914-1lpl26eo	24	33	for	for	IN
cord-309914-1lpl26eo	24	34	.	.	.
cord-309914-1lpl26eo	24	35	 	 	_SP
cord-309914-1lpl26eo	25	1	Should	Should	NNP
cord-309914-1lpl26eo	25	2	biologics	biologic	NNS
cord-309914-1lpl26eo	25	3	for	for	IN
cord-309914-1lpl26eo	25	4	psoriasis	psoriasis	NN
cord-309914-1lpl26eo	25	5	be	be	VB
cord-309914-1lpl26eo	25	6	interrupted	interrupt	VBN
cord-309914-1lpl26eo	25	7	in	in	IN
cord-309914-1lpl26eo	25	8	the	the	DT
cord-309914-1lpl26eo	25	9	era	era	NN
cord-309914-1lpl26eo	25	10	of	of	IN
cord-309914-1lpl26eo	25	11	Inflammatory	Inflammatory	NNP
cord-309914-1lpl26eo	25	12	Diseases	Diseases	NNPS
cord-309914-1lpl26eo	25	13	liver	liver	NN
cord-309914-1lpl26eo	25	14	abscess	abscess	NN
cord-309914-1lpl26eo	25	15	(	(	-LRB-
cord-309914-1lpl26eo	25	16	1	1	CD
cord-309914-1lpl26eo	25	17	)	)	-RRB-
cord-309914-1lpl26eo	25	18	,	,	,
cord-309914-1lpl26eo	25	19	pleural	pleural	JJ
cord-309914-1lpl26eo	25	20	effusion	effusion	NN
cord-309914-1lpl26eo	25	21	(	(	-LRB-
cord-309914-1lpl26eo	25	22	1	1	CD
cord-309914-1lpl26eo	25	23	)	)	-RRB-
cord-309914-1lpl26eo	25	24	,	,	,
cord-309914-1lpl26eo	25	25	pyelonephritis	pyelonephritis	NN
cord-309914-1lpl26eo	25	26	(	(	-LRB-
cord-309914-1lpl26eo	25	27	1	1	CD
cord-309914-1lpl26eo	25	28	)	)	-RRB-
cord-309914-1lpl26eo	25	29	117	117	CD
cord-309914-1lpl26eo	25	30	2	2	CD
cord-309914-1lpl26eo	25	31	.	.	.
cord-309914-1lpl26eo	26	1	10	10	CD
cord-309914-1lpl26eo	26	2	mg	mg	NNP
cord-309914-1lpl26eo	26	3	dose	dose	NN
cord-309914-1lpl26eo	26	4	-	-	HYPH
cord-309914-1lpl26eo	26	5	anal	anal	JJ
cord-309914-1lpl26eo	26	6	abscess	abscess	NN
cord-309914-1lpl26eo	26	7	(	(	-LRB-
cord-309914-1lpl26eo	26	8	1	1	CD
cord-309914-1lpl26eo	26	9	)	)	-RRB-
cord-309914-1lpl26eo	26	10	,	,	,
cord-309914-1lpl26eo	26	11	cellulitis	cellulitis	NN
cord-309914-1lpl26eo	26	12	(	(	-LRB-
cord-309914-1lpl26eo	26	13	1	1	CD
cord-309914-1lpl26eo	26	14	)	)	-RRB-
cord-309914-1lpl26eo	26	15	,	,	,
cord-309914-1lpl26eo	26	16	febrile	febrile	JJ
cord-309914-1lpl26eo	26	17	infection	infection	NN
cord-309914-1lpl26eo	26	18	(	(	-LRB-
cord-309914-1lpl26eo	26	19	1	1	CD
cord-309914-1lpl26eo	26	20	)	)	-RRB-
cord-309914-1lpl26eo	26	21	,	,	,
cord-309914-1lpl26eo	26	22	otitis	otitis	NN
cord-309914-1lpl26eo	26	23	externa	externa	NNS
cord-309914-1lpl26eo	26	24	(	(	-LRB-
cord-309914-1lpl26eo	26	25	1	1	CD
cord-309914-1lpl26eo	26	26	)	)	-RRB-
cord-309914-1lpl26eo	26	27	,	,	,
cord-309914-1lpl26eo	26	28	pneumonia	pneumonia	NN
cord-309914-1lpl26eo	26	29	(	(	-LRB-
cord-309914-1lpl26eo	26	30	1	1	CD
cord-309914-1lpl26eo	26	31	)	)	-RRB-
cord-309914-1lpl26eo	26	32	118	118	CD
cord-309914-1lpl26eo	26	33	3	3	CD
cord-309914-1lpl26eo	26	34	.	.	.
cord-309914-1lpl26eo	27	1	10	10	CD
cord-309914-1lpl26eo	27	2	mg	mg	NNP
cord-309914-1lpl26eo	27	3	dose	dose	NN
cord-309914-1lpl26eo	27	4	-furuncle	-furuncle	NNP
cord-309914-1lpl26eo	27	5	(	(	-LRB-
cord-309914-1lpl26eo	27	6	1	1	CD
cord-309914-1lpl26eo	27	7	)	)	-RRB-
cord-309914-1lpl26eo	27	8	119	119	CD
cord-309914-1lpl26eo	27	9	4	4	CD
cord-309914-1lpl26eo	27	10	.	.	.
cord-309914-1lpl26eo	28	1	1	1	CD
cord-309914-1lpl26eo	28	2	mg	mg	NN
cord-309914-1lpl26eo	28	3	dose	dose	NN
cord-309914-1lpl26eo	28	4	-peri	-peri	NN
cord-309914-1lpl26eo	28	5	-	-	HYPH
cord-309914-1lpl26eo	28	6	tonsillitis	tonsillitis	NN
cord-309914-1lpl26eo	28	7	PNA	PNA	NNP
cord-309914-1lpl26eo	28	8	(	(	-LRB-
cord-309914-1lpl26eo	28	9	8)	8)	NNP
cord-309914-1lpl26eo	28	10	,	,	,
cord-309914-1lpl26eo	28	11	122	122	CD
cord-309914-1lpl26eo	28	12	sinusitis	sinusitis	NN
cord-309914-1lpl26eo	28	13	(	(	-LRB-
cord-309914-1lpl26eo	28	14	1	1	CD
cord-309914-1lpl26eo	28	15	)	)	-RRB-
cord-309914-1lpl26eo	28	16	,	,	,
cord-309914-1lpl26eo	28	17	sepsis	sepsis	NN
cord-309914-1lpl26eo	28	18	(	(	-LRB-
cord-309914-1lpl26eo	28	19	1	1	CD
cord-309914-1lpl26eo	28	20	)	)	-RRB-
cord-309914-1lpl26eo	28	21	,	,	,
cord-309914-1lpl26eo	28	22	lower	low	JJR
cord-309914-1lpl26eo	28	23	respiratory	respiratory	JJ
cord-309914-1lpl26eo	28	24	infection	infection	NN
cord-309914-1lpl26eo	28	25	(	(	-LRB-
cord-309914-1lpl26eo	28	26	1	1	CD
cord-309914-1lpl26eo	28	27	)	)	-RRB-
cord-309914-1lpl26eo	28	28	123	123	CD
cord-309914-1lpl26eo	28	29	7	7	CD
cord-309914-1lpl26eo	28	30	.	.	.
cord-309914-1lpl26eo	29	1	15	15	CD
cord-309914-1lpl26eo	29	2	mg	mg	NN
cord-309914-1lpl26eo	29	3	dose	dose	NN
cord-309914-1lpl26eo	29	4	-	-	HYPH
cord-309914-1lpl26eo	29	5	viral	viral	JJ
cord-309914-1lpl26eo	29	6	infection	infection	NN
cord-309914-1lpl26eo	29	7	(	(	-LRB-
cord-309914-1lpl26eo	29	8	1	1	CD
cord-309914-1lpl26eo	29	9	)	)	-RRB-